Serpins in Hemostasis as Therapeutic Targets for Bleeding or Thrombotic Disorders

Elsa P Bianchini; Claire Auditeau; Mahita Razanakolona; Marc Vasse; Delphine Borgel

doi:10.3389/fcvm.2020.622778

Serpins in Hemostasis as Therapeutic Targets for Bleeding or Thrombotic Disorders

Front Cardiovasc Med. 2021 Jan 7:7:622778. doi: 10.3389/fcvm.2020.622778. eCollection 2020.

Authors

Elsa P Bianchini¹, Claire Auditeau¹, Mahita Razanakolona¹, Marc Vasse^{1

2}, Delphine Borgel^{1

3}

Affiliations

¹ HITh, UMR_S1176, Institut National de la Santé et de la Recherche Médicale, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
² Service de Biologie Clinique, Hôpital Foch, Suresnes, France.
³ Laboratoire d'Hématologie Biologique, Hôpital Necker, APHP, Paris, France.

Abstract

Bleeding and thrombotic disorders result from imbalances in coagulation or fibrinolysis, respectively. Inhibitors from the serine protease inhibitor (serpin) family have a key role in regulating these physiological events, and thus stand out as potential therapeutic targets for modulating fibrin clot formation or dismantling. Here, we review the diversity of serpin-targeting strategies in the area of hemostasis, and detail the suggested use of modified serpins and serpin inhibitors (ranging from small-molecule drugs to antibodies) to treat or prevent bleeding or thrombosis.

Keywords: antithrombin (AT); plasminogen activator inhibitor 1 (PAI-1); protease nexin I (PN-1); protein Z-dependent protease inhibitor (ZPI); serpin (serine proteinase inhibitor); therapy.

Publication types

Review